Nanobiotix (NBTX)
NASDAQ:NBTX
Want to see NBTX full AI Analyst Report?
NBTX Stock Chart & Stats
$33.79
-$0.03(-1.02%)
At close: 4:00 PM EST
$33.79
-$0.03(-1.02%)
Day’s Range― - ―
52-Week Range$3.26 - $41.89
Previous CloseN/A
Volume23.08K
Average Volume (3M)68.02K
Market Cap
$1.50B
Enterprise Value$1.72B
Total Cash (Recent Filing)$52.75M
Total Debt (Recent Filing)$95.32M
Price to Earnings (P/E)―
Beta0.73
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.50
Shares Outstanding48,401,120
10 Day Avg. Volume61,649
30 Day Avg. Volume68,024
Financial Highlights & Ratios
PEG Ratio0.60
Price to Book (P/B)-11.14
Price to Sales (P/S)31.74
P/FCF Ratio-27.70
Enterprise Value/Market Cap1.15
Enterprise Value/Revenue58.07
Enterprise Value/Gross Profit58.07
Enterprise Value/Ebitda-142.64
Forecast
1Y Price Target
$34.33Price Target Upside1.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.12
Revenue Forecast (FY)$45.93M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy SignalsEarly clinical data, including pronounced survival benefits and higher response rates in head and neck cancer, indicate meaningful efficacy that supports confidence in ongoing confirmatory trials.
Platform VersatilityNanobiotix's physics-based platform is not limited by biological targets and can be applied across many tumor types, supporting multiple development paths beyond a single indication.
Strategic PartnershipsA collaboration with a major pharmaceutical company, including work with Johnson & Johnson on the R3 program, validates the technology, brings development expertise, and strengthens commercialization prospects.
Bears Say
Durability And Follow-up RiskExpansion into cisplatin-eligible patients is being assessed mainly by short-term response rates, creating uncertainty about the durability of benefit without longer follow-up data.
Nanobiotix News
NBTX FAQ
What was Nanobiotix’s price range in the past 12 months?
Nanobiotix lowest stock price was $3.26 and its highest was $41.89 in the past 12 months.
What is Nanobiotix’s market cap?
Nanobiotix’s market cap is $1.50B.
When is Nanobiotix’s upcoming earnings report date?
Nanobiotix’s upcoming earnings report date is May 20, 2026 which is in 13 days.
How were Nanobiotix’s earnings last quarter?
Nanobiotix released its earnings results on Mar 31, 2026. The company reported -$0.453 earnings per share for the quarter, beating the consensus estimate of -$0.507 by $0.054.
Is Nanobiotix overvalued?
According to Wall Street analysts Nanobiotix’s price is currently Undervalued.
Does Nanobiotix pay dividends?
Nanobiotix does not currently pay dividends.
What is Nanobiotix’s EPS estimate?
Nanobiotix’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nanobiotix have?
Nanobiotix has 48,401,120 shares outstanding.
What happened to Nanobiotix’s price movement after its last earnings report?
Nanobiotix reported an EPS of -$0.453 in its last earnings report, beating expectations of -$0.507. Following the earnings report the stock price went up 10.366%.
Which hedge fund is a major shareholder of Nanobiotix?
Currently, no hedge funds are holding shares in NBTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nanobiotix Stock Smart Score
Company Description
Nanobiotix
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
NBTX Company Deck
NBTX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Positive overall. The company reported meaningful financial and operational improvements driven by (a) removal of large development obligations via the Janssen amendment, (b) nondilutive royalty financing that materially strengthens near-term liquidity, and (c) clinical progress across multiple programs including encouraging early CONVERGE lead-in data and continued Curadigm platform advancement (patents, MTAs, CMC/GMP start). Key risks remain: the FY2025 revenue uplift is largely a one‑time accounting effect, clinical readouts (notably CONVERGE and the Phase III head & neck study) are controlled by J&J and many pivotal data points are not expected until 2027, and the stated runway depends on receipt of remaining financing and potential milestone receipts. On balance, the positives (stronger cash runway, lower burn, decreased net loss, strategic financing, multiple clinical catalysts and platform progress) outweigh the listed risks and uncertainties.View all NBTX earnings summariesNBTX Stock 12 Month Forecast
Average Price Target
$34.33
▲(1.61% Upside)
Technical Analysis
―
Bicara Therapeutics Inc.
―
Zenas BioPharma, Inc.
―
Upstream Bio, Inc.
―
Septerna, Inc.
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
11.62% Other Institutional Investors
88.37% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---